NEUROCENTRIA

Neurocentria is a clinical-stage pharmaceutical company founded with the mission to discover and develop treatments for neurological diseases, including cognitive impairment and neuropsychiatric disorders. Neurocentria's research has focused on synaptic function, the elemental unit of neuronal communication and whose dysfunction is a common factor underlying both cognitive impairment and neuropsychiatric disorder. Two decades of research at Stanford, MIT, and Tsinghua University culminated in an understanding of the biology needed to restore synaptic function.